Amarin Corporation plc - American Depositary Receipt (AMRN)
NASDAQ (CM) NASDAQ (CM) Primary 
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript
Amarin Corporation plc ( AMRN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Aaron Berg - CEO, President & Director Peter Fishman - Senior VP & CFO Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Mazahir Alimohamed - Leerink Partners LLC, Research Division Presentation Operator Welcome to Amarin Corporation's conference call to discuss its third quarter 2025 financial results. I would like to turn the conference call over to Bob Burrows, Investor Relations for Amarin.
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?
Amarin (AMRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Aaron D. Berg - CEO, President & Director Mark Marmur - Corporate Participant Peter L.
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
3 Strong Buy Breakout Stocks for Explosive Returns
MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.
Best Momentum Stock to Buy for June 27th
GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.
